Trial Profile
Effects of Co-infusion of Peptide YY 3-36 and Glucagon-like peptide-1 on Insulin Secretion and Insulin Sensitivity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2013
Price :
$35
*
At a glance
- Drugs Glucagon-like peptide-1 (Primary) ; Peptide YY 3-36 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Jul 2013 New trial record
- 18 Jun 2013 Results presented at the 95th Annual Meeting of the Endocrine Society.